Pulse Biosciences, Inc.
53.02USD
+0.3400 (+0.65%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on PLSE.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 700.0K | 0.0 | 0.0 | 350.0K | 2.0M | 5.7M |
| Q1 | 444.0K | 0.0 | 0.0 | 0.0 | 401.0K | — |
| Q2 | 265.0K | 0.0 | 0.0 | 0.0 | 434.0K | — |
| Q3 | 0.0 | 0.0 | 0.0 | 86.0K | 521.7K | — |
| Q4 | -9.0K* | 0.0* | 0.0* | 264.0K* | 695.0K | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -1.72 | -.850 | -.920 | -1.08 | -1.11 | -1.17 |
| Q1 | -.580 | -.260 | -.180 | -.250 | -.270 | — |
| Q2 | -.440 | -.220 | -.200 | -.280 | -.360 | — |
| Q3 | -.490 | -.190 | -.210 | -.290 | -.287 | — |
| Q4 | -.220* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -.210* |
| -.320* |
| -.260* |
| -.300 |
| — |
Debt level and coverage